Skip to main content Skip to search Skip to main navigation
News: Medical Devices

MedTech: Call for Structural Reform of MDR and IVDR

MedTech Europe, along with 34 national associations, published an open letter to EU Health Commissioner Stella Kyriakides on 14 September 2023.

In the 3-page letter, the stakeholders, on behalf of the MedTech industry, point out that an urgent and comprehensive reform is necessary to address the challenges created by the Medical Devices Regulation (MDR (EU) 2017/745) and the In Vitro Diagnostic Medical Devices Regulation (IVDR (EU) 2017/746).

One of the original objectives of the regulations, to establish a stable and transparent regulatory framework that ensures a high level of safety and health while supporting innovation, has not been implemented sufficiently after more than six years, they argue. What is problematic is that both medical technology innovations already on the market and future innovations have a hard time reaching European patients and healthcare systems.

According to the trade groups, structural problems in the legal framework of the MDR and IVDR are to blame. They are therefore calling for comprehensive changes in the regulations to minimise the lack of agility and innovation.

Trade associations are calling for three main improvements:

  • A more efficient and fit-for-purpose CE marking system,
  • a system that supports innovation in medical technology, and
  • a single structure to oversee and manage the regulatory system.

In addition to the demands, the open letter also proposes solutions and measures to improve the current situation.

Stella Kyriakides was offered the cooperation and support of the industry:"We stand ready to work together with you and the European Commission services to address this pressing situation and work toward the comprehensive structural reform necessary to achieve the stated objectives of the regulations.."


Source:

MedTech Europe: Open Letter

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

News: EMA

EMA Clarifies Batch Numbering for Parallel-Traded Medicines

EMA updated its GMP/GDP Q&A collection by revising the answer to Question 4 concerning Chapter 5 of the EU GMP Guide. It explains which batch numbers should appear on the packaging of parallel-traded medicines.

Read more
Question of the Week | GMP-Verlag

Why is it Important to use Consistent Microbiological Air Monitoring Methods in Pharmaceutical Cleanrooms?

Here's the answer:
Read more
Cleaning Validation: When PDE Reports and the Worst-Case Selection do not Align

Cleaning Validation: When PDE Reports and the Worst-Case Selection do not Align

Robust PDE reports form the basis of risk-based cleaning validation. This article highlights common deficiencies identified during GMP inspections and explains how they can be avoided.

Read more
News: Europe

EDQM: New Working Party on 3D-printed Medicinal Products

The European Pharmacopoeia Commission (EPC) approved the creation of a working party on 3D-printed medicinal products. Its aim is to support the development of appropriate quality standards in the European Pharmacopoeia (Ph. Eur.).
Read more
EMA: 14 New Nitrosamines for Appendix 1

EMA: 14 New Nitrosamines for Appendix 1

Appendix 1 of EMA’s Questions and Answers on nitrosamine impurities has been updated. This appendix contains acceptable intakes (AIs) established for N-nitrosamines.
Read more
WHO: Draft Revision of its Guidelines on Quality Risk Management

WHO: Draft Revision of its Guidelines on Quality Risk Management

WHO published a revised draft of its “WHO guidelines on quality risk management”. Working document QAS/26.994 is open for public comment until 15 November 2026.
Read more
Previous
Next